title: At the bench: adoptive cell therapy for melanoma.
abstract: The cellular and molecular principles that furnish the foundation for ACT of melanoma and their implications for further clinical research are reviewed. The parallel advances in basic immunology, preclinical animal studies, and clinical trials over the last two decades have been integrated successfully with improvements in technology to produce an effective ACT strategy for patients with melanoma. From the initial observation that tumors could be treated effectively by the transfer of immune cells to current strategies using preconditioning with myeloablative therapy before adoptive transfer of native or genetically altered T cells, the role of preclinical animal models is discussed. The importance of the pmel transgenic mouse model in the determination of the mechanisms of lymphodepletion, the ongoing work to identify the optimal T cells for adoptive immunotherapy, and the early impact of the emerging discipline of synthetic biology are highlighted. The clinical consequences of the research described herein are reviewed in the companion manuscript.
authors.affiliation: Earle A. Chiles Research Institute, Providence Cancer Center, Portland, Oregon, USA walter.urba@providence.org.
authors.forename: Walter J
authors.initials: WJ
authors.lastname: Urba
mesh_terms: D000818:Animals; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein / Q000276:immunology; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D008212:Lymphocyte Depletion; D008545:Melanoma / Q000628:therapy*; D015202:Protein Engineering; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: C568771:CLMP protein, human; D062727:Coxsackie and Adenovirus Receptor-Like Membrane Protein; D007376:Interleukin-2; D011948:Receptors, Antigen, T-Cell
keywords: cytokines; lymphoid depletion; murine; transgenic